| Name | Title | Contact Details |
|---|
Aldie Foundation Inc is a Doylestown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
eviCore healthcare offers proven, diversified medical benefit management solutions that help clients reduce costs while increasing quality of care for their members. The company provides these solutions to managed care organizations and risk-bearing provider organizations serving commercial, Medicare and Medicaid populations. Powered by a team of specialized medical professional resources, extensive evidence-based guidelines and advanced technologies, the company supports clients by ensuring the right evidence-based care is delivered at the right time to the right patient at the right site of care. Flexible medical benefit management solutions are offered in: Diagnostic Testing and Imaging; Cardiology; Comprehensive Musculoskeletal and Pain Management; Medical and Radiation Oncology; Sleep Services; Lab Management; and Post-Acute Care (including participating in the CMS Bundled Payments for Care Improvement Initiative). eviCore is proud to help over 80 million Americans receive higher quality, lower cost healthcare.
Injury Care Associates is a physician-led occupational health clinic that specializes in helping employees get back to work and back to life after an injury. They offer workers compensation and employee health services in the Denver metro area.
CGIT is a Quincy, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.